More Related Content
What's hot
What's hot (14)
Similar to Criam pitch deck
Similar to Criam pitch deck (20)
Recently uploaded
Recently uploaded (20)
Criam pitch deck
- 1. THE ONLY AUTOMATIC POINT–OF–CARE DIAGNOSTIC PLATFORM FOR MOBILITY
- 2. EVERY SECOND SOMEONE IN THE WORLD NEEDS BLOOD
- 5. PORTABLE MEDICAL DEVICE WHICH IDENTIFIES HUMAN BLOODTYPE FAST Blood-type detection in 3mins PORTABLE To be used whenever and wherever INEXPENSIVE 80% cheaper than other lab machines DECREASES O- dependency
- 6. FEATURES Minimum process time (min.) ≈ 11 ≈ 30 ≈ 26 >9 > 9 ≈ 25 3 Emergency use Portability # Of samples 20 224 N/A 96 48 42 1 Price $ 95.000 + $ 100.000 + $ 100.000 + $ 100.000 $ 16.000 According to the WHO, the price range for a ABO blood type system can have an average price range of $ 115.000 to $ 225.000 DIFFERENTIATORS “With the mission to transform transfusion diagnostics through the provision of the comprehensive automated testing solutions, improving patient outcomes, delivering major efficiencies”. The healthcare transfusion market needs development and disruption. Quotient is changing transfusion diagnostics with a transformative and disruptive diagnostics platform at laboratory/hospital environment while CRIAM wants to do it in a portable way. Quotient already secured the needed investment and is now considered a visionary at this space. OTHER:
- 7. DEVICE AS A PLATFORM HIV . BRUCELLA . LYME DISEASE . SYPHILLIS . MONONUCLEOSIS . MENINGITIS
- 8. OUR TECHNOLOGY: MACHINE LEARNING | COMPUTER VISION
- 9. HEALTHCARE MARKET GOVERNMENTS MILITARY NGO’S POTENTIAL MARKET More than 170.000 Hospitals and Medical institutions More than 100.000 Ground ambulance Vehicles worldwide $4B>
- 11. PRICES: • Cartridge (wholesale) - $ 12 • Cartrdige (retail) - $ 16 PRICE STRATEGY: • Device (wholesale) - $ 11.200 • Device (retail) - $ 16.000 • Or no cost depending on annual cartridge commitment When a new disease detection is developed, it will be possible to update the device with disease algorithms – through OTA or USB – with an annual based fee. Device Retail revenue stream DISTRIBUTOR MARGIN: 35% Cartridges Recurrent revenue stream DISTRIBUTOR MARGIN: 33% We aim to adopt a Nespresso approach by emphasizing recurrent revenue stream from the cartridges leveraging on economy of scale. Software Updates Not included in this business case BUSINESS MODEL
- 12. VITOR ANA FILIPE FERNANDO CAROLINA OUR TEAM RITA
- 13. DR. BAKRI DR. MACHADO DR. SOUSADR. CARVALHO OUR ADVISORS AND PARTNERS
- 14. PROJECT RECOGNITION 1st place Microsoft Imagine Cup Worldwide 1st place “Nação Inovadora” Top 15 HAX Acceleration Program (sponsored by Johnson & Johnson) Showcasing at CES in LA Top 8 Health Startups at Pioneers ’17 Showcasing at MUC Summit in Munich and WebSummit ’16 and ‘17 Top 5 Startup Package Austria (Out – Dec ‘17) Top 10 Showcasing at Health Pioneers (Oct ‘17) H2020 Seal of Excellence & Portuguese Grant ($340.000) EU Top 50 Nov’ 17
- 15. HOW SUCCESS LOOKS LIKE IN 18 MONTHS Month 1 • CMO on-board Month 2 Month 3 • Start of CE Mark and FDA process (regulatory filing) Month 4 • Distribution Agreements signed (top 5 markets) Month 5 • 10 final devices ready (for blood-type and subtype) Month 9 • Ready to manufacture (outsourcing scale-up); • Scientific publications in the Top Science Magazines Month 10 • Distribution Agreement/Market Access (EU/EMEA) Month 12 • Market expansion – Asia PAC – Market Access Month 14 • Market expansion – UAE – Market Access Month 18 • US launch – Market • Access Diseases • Pipeline R&D
- 16. Ready for commercialization Pre-clinical trials performed Scientific papers published Partnership with Birmingham Bio-Hub US Company in Delaware (Q1 2018) SOSV commitment for the round Industrialization R&D Marketing HRIP Validation + + + + $1.9M FUNDING NEEDS
- 17. PLATFORM APPROACH TO MONITOR, CONTROL AND CONTAIN DISEASES WORLDWIDE